Il ruolo della chirurgia conservativa nei tumori ova-rici maligni a cellule germinali

Translated title of the contribution: The role of conservative surgery in malignant ovarian germ cell tumors

G. Mangili, V. Giorgione, C. Sigismondi, E. Rabaiotti, R. Viganò, P. De Marzi, M. Candiani

Research output: Contribution to journalArticle

Abstract

The role of conservative surgery in malignant ovarian germ cell tumors. Malignant ovarian germ cell tumors (MOGCTs) represent approximately 5% of all ovarian malignancies and occur primarily in young women. They are diagnosed at stage I in 50 to 70% of cases and show survival rates up to 90% in early MOGCTs and up to 75% in advanced stages. This success is due to a mul-timodality treatment with primary surgery followed by platinum-based chemotherapy introduced since the 1980s. The aim of this study was to review current management and prognosis of patients with MOGCTs underwent conservative surgery. In stage I MOCGTs unilateral salpingo-oophorec-tomy and adjuvant chemotherapy are considered the standard treatment, except for stage IA dysgermino-ma and stage I immature teratoma in which surgery alone is the treatment of choice. Standard treatment for patients with stage II-IV MOGCT is cytoreduction followed by BEP (bleomycin, etoposide, platinum) chemotherapy. In advanced MOGCTs, preservation of fertility is also advised, considering that approximately 80% of patients will be long-term survivors, even if they have residual disease after cytoreductive surgery. In patients undergoing fertility-sparing surgery the number of pregnancies carried to term is high and adverse effects are not reported in the offspring. In conclusion, MOGCTs are rare malignancies that mainly affect young women and prognosis is excellent, so conservative surgery of MOGCTs has to be considered the gold standard.

Original languageItalian
Pages (from-to)76-83
Number of pages8
JournalItalian Journal of Gynaecology and Obstetrics
Volume25
Issue number3-4
Publication statusPublished - 2013

Fingerprint

Germ Cell and Embryonal Neoplasms
Platinum
Fertility Preservation
Drug Therapy
Teratoma
Bleomycin
Etoposide
Therapeutics
Adjuvant Chemotherapy
Fertility
Survivors
Neoplasms
Survival Rate
Pregnancy

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Il ruolo della chirurgia conservativa nei tumori ova-rici maligni a cellule germinali. / Mangili, G.; Giorgione, V.; Sigismondi, C.; Rabaiotti, E.; Viganò, R.; De Marzi, P.; Candiani, M.

In: Italian Journal of Gynaecology and Obstetrics, Vol. 25, No. 3-4, 2013, p. 76-83.

Research output: Contribution to journalArticle

Mangili, G, Giorgione, V, Sigismondi, C, Rabaiotti, E, Viganò, R, De Marzi, P & Candiani, M 2013, 'Il ruolo della chirurgia conservativa nei tumori ova-rici maligni a cellule germinali', Italian Journal of Gynaecology and Obstetrics, vol. 25, no. 3-4, pp. 76-83.
Mangili G, Giorgione V, Sigismondi C, Rabaiotti E, Viganò R, De Marzi P et al. Il ruolo della chirurgia conservativa nei tumori ova-rici maligni a cellule germinali. Italian Journal of Gynaecology and Obstetrics. 2013;25(3-4):76-83.
Mangili, G. ; Giorgione, V. ; Sigismondi, C. ; Rabaiotti, E. ; Viganò, R. ; De Marzi, P. ; Candiani, M. / Il ruolo della chirurgia conservativa nei tumori ova-rici maligni a cellule germinali. In: Italian Journal of Gynaecology and Obstetrics. 2013 ; Vol. 25, No. 3-4. pp. 76-83.
@article{6c5523a9397746a7b19d80b1d5ecd06b,
title = "Il ruolo della chirurgia conservativa nei tumori ova-rici maligni a cellule germinali",
abstract = "The role of conservative surgery in malignant ovarian germ cell tumors. Malignant ovarian germ cell tumors (MOGCTs) represent approximately 5{\%} of all ovarian malignancies and occur primarily in young women. They are diagnosed at stage I in 50 to 70{\%} of cases and show survival rates up to 90{\%} in early MOGCTs and up to 75{\%} in advanced stages. This success is due to a mul-timodality treatment with primary surgery followed by platinum-based chemotherapy introduced since the 1980s. The aim of this study was to review current management and prognosis of patients with MOGCTs underwent conservative surgery. In stage I MOCGTs unilateral salpingo-oophorec-tomy and adjuvant chemotherapy are considered the standard treatment, except for stage IA dysgermino-ma and stage I immature teratoma in which surgery alone is the treatment of choice. Standard treatment for patients with stage II-IV MOGCT is cytoreduction followed by BEP (bleomycin, etoposide, platinum) chemotherapy. In advanced MOGCTs, preservation of fertility is also advised, considering that approximately 80{\%} of patients will be long-term survivors, even if they have residual disease after cytoreductive surgery. In patients undergoing fertility-sparing surgery the number of pregnancies carried to term is high and adverse effects are not reported in the offspring. In conclusion, MOGCTs are rare malignancies that mainly affect young women and prognosis is excellent, so conservative surgery of MOGCTs has to be considered the gold standard.",
keywords = "Chemotherapy, Conservative surgery, Fertility preservation, Malignant ovarian germ cell tumors",
author = "G. Mangili and V. Giorgione and C. Sigismondi and E. Rabaiotti and R. Vigan{\`o} and {De Marzi}, P. and M. Candiani",
year = "2013",
language = "Italian",
volume = "25",
pages = "76--83",
journal = "Italian Journal of Gynaecology and Obstetrics",
issn = "1121-8339",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "3-4",

}

TY - JOUR

T1 - Il ruolo della chirurgia conservativa nei tumori ova-rici maligni a cellule germinali

AU - Mangili, G.

AU - Giorgione, V.

AU - Sigismondi, C.

AU - Rabaiotti, E.

AU - Viganò, R.

AU - De Marzi, P.

AU - Candiani, M.

PY - 2013

Y1 - 2013

N2 - The role of conservative surgery in malignant ovarian germ cell tumors. Malignant ovarian germ cell tumors (MOGCTs) represent approximately 5% of all ovarian malignancies and occur primarily in young women. They are diagnosed at stage I in 50 to 70% of cases and show survival rates up to 90% in early MOGCTs and up to 75% in advanced stages. This success is due to a mul-timodality treatment with primary surgery followed by platinum-based chemotherapy introduced since the 1980s. The aim of this study was to review current management and prognosis of patients with MOGCTs underwent conservative surgery. In stage I MOCGTs unilateral salpingo-oophorec-tomy and adjuvant chemotherapy are considered the standard treatment, except for stage IA dysgermino-ma and stage I immature teratoma in which surgery alone is the treatment of choice. Standard treatment for patients with stage II-IV MOGCT is cytoreduction followed by BEP (bleomycin, etoposide, platinum) chemotherapy. In advanced MOGCTs, preservation of fertility is also advised, considering that approximately 80% of patients will be long-term survivors, even if they have residual disease after cytoreductive surgery. In patients undergoing fertility-sparing surgery the number of pregnancies carried to term is high and adverse effects are not reported in the offspring. In conclusion, MOGCTs are rare malignancies that mainly affect young women and prognosis is excellent, so conservative surgery of MOGCTs has to be considered the gold standard.

AB - The role of conservative surgery in malignant ovarian germ cell tumors. Malignant ovarian germ cell tumors (MOGCTs) represent approximately 5% of all ovarian malignancies and occur primarily in young women. They are diagnosed at stage I in 50 to 70% of cases and show survival rates up to 90% in early MOGCTs and up to 75% in advanced stages. This success is due to a mul-timodality treatment with primary surgery followed by platinum-based chemotherapy introduced since the 1980s. The aim of this study was to review current management and prognosis of patients with MOGCTs underwent conservative surgery. In stage I MOCGTs unilateral salpingo-oophorec-tomy and adjuvant chemotherapy are considered the standard treatment, except for stage IA dysgermino-ma and stage I immature teratoma in which surgery alone is the treatment of choice. Standard treatment for patients with stage II-IV MOGCT is cytoreduction followed by BEP (bleomycin, etoposide, platinum) chemotherapy. In advanced MOGCTs, preservation of fertility is also advised, considering that approximately 80% of patients will be long-term survivors, even if they have residual disease after cytoreductive surgery. In patients undergoing fertility-sparing surgery the number of pregnancies carried to term is high and adverse effects are not reported in the offspring. In conclusion, MOGCTs are rare malignancies that mainly affect young women and prognosis is excellent, so conservative surgery of MOGCTs has to be considered the gold standard.

KW - Chemotherapy

KW - Conservative surgery

KW - Fertility preservation

KW - Malignant ovarian germ cell tumors

UR - http://www.scopus.com/inward/record.url?scp=84895163204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895163204&partnerID=8YFLogxK

M3 - Articolo

VL - 25

SP - 76

EP - 83

JO - Italian Journal of Gynaecology and Obstetrics

JF - Italian Journal of Gynaecology and Obstetrics

SN - 1121-8339

IS - 3-4

ER -